Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk’s Ozempic Gets FDA Approval
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.
F.D.A. Approves Ozempic to Treat Kidney Disease
The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both type 2 diabetes and chronic kidney disease.
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of chronic kidney disease and the organ's failure, and death due to heart problems in adults with type 2 diabetes.
Novo’s Ozempic Notches Approval for Kidney Disease, Widening Use
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use.
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
Medical News Today
6h
A key protein may help Ozempic users retain muscle mass while losing fat
Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...
3h
Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Psychology Today
1d
Nature’s Ozempic
A gut microbe has been identified that mimics the effects of Ozempic to mitigate diabetes and obesity. Here's how to take ...
5h
Ozempic, Wegovy may help mental health, substance disorders
An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...
5h
on MSN
Skinny ‘Ozempic’ phones are making a comeback: ‘A nostalgic twist’
Smartphones are taking a shot at slenderizing in a nod to Ben Stiller’s itty-bitty mobile in the early-aughts classic ...
purewow on MSN
6h
Can Ozempic Lead to Divorce? Here's Everything to Know, According to a Psychologist
Ozempic divorce is current shorthand for the relationship difficulty that follows weight loss from GLP-1 drugs. I talk to a weight loss psychologist about what clinical, cultural and mental health ...
1d
Doctors Foreshadow Side Effects Of Ozempic As the Medication Takes Over Hollywood
Ozempic has taken the world of Hollywood by storm — and now, doctors are advising people to rein it in a little. Of course, ...
5d
on MSN
Ozempic’s health benefits keep growing, but are the risks worth it?
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Novo Nordisk
Kidney disease
United States
Oprah Winfrey
Hollywood
Feedback